Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Calcium. 2010 Sep;20(9):1394-400. doi: CliCa100913941400.

[Pharmaceutical treatment for patients with hip fracture].

[Article in Japanese]

Author information

1
School of Health Science, Faculty of Medicine,/Rehabilitation Division, Tottori University.

Abstract

It is well known that fracture risk, including second hip fracture, is elevated in patients with hip fracture. Therefore, they are good candidate for pharmaceutical treatment of osteoporosis to prevent subsequent fractures. Nitrogen-containing bisphosphonate is the first line drug for their treatment. Teriparatide, which has been recently approved in Japan for the treatment of osteoporosis, has osteogenic effects and is expected to prevent fractures in patients with hip fracture.

PMID:
20808048
DOI:
CliCa100913941400
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center